Piper Sandler Reaffirms Vertex Pharmaceuticals as a “Buy”: Examining Analyst Insights and Market Performance
In the competitive healthcare sector, Vertex Pharmaceuticals (VRTX) continues to receive strong support from analysts. Piper Sandler’s Christopher Raymond recently reiterated a “Buy” rating for Vertex, setting a price target of $535, indicating confidence in the company’s growth potential. This valuation is well above Vertex’s closing price of $474.91, suggesting an optimistic outlook for the…